Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 289 participants.
Also called NCT05085275
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 289 participants
- Sponsor
- Registry
-
NCT05085275
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT05085275. Randomized; quadruple masking; primary purpose treatment. Start 2022-03-30 (actual); primary completion 2024-01-24 (actual). Results posted on 2025-08-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease
- Acronym
- FRONTIER
- Condition
- Anemia, Iron Deficiency
- Condition
- Hyperphosphatemia
- Condition
- Renal Insufficiency, Chronic
- Condition
- Renal Anemia
- Condition
- Disease Progression
- Condition
- Cardiovascular
- Condition
- Iron
- Intervention (Drug)
- Ferric Citrate 1 GM Oral Tablet [AURYXIA]
- Intervention (Drug)
- Placebo
- Lead sponsor
- USRC Kidney Research
- Collaborator
- Akebia Therapeutics
Record details
- Record id
cardio:ct-nct05085275- Content hash
bbf699bdeac42defffcc2bedf26ad0b24d107b96c7b991a9947ced3d479d27b9